Spornar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spornar

What is Spornar? (Itraconazole)

Property Description
Active Ingredient Itraconazole
Pharmacological Class Systemic Antifungal Agent (Triazole)
Available Forms Capsule, Oral Solution (Liquid)
Route of Administration Oral
Origin Synthetic
General Purpose Controlling and eliminating fungal infections

What Kind of Medicine is Spornar? (Definition, Class, and Purpose)

Spornar is a brand name for the active drug itraconazole, a synthetic triazole antifungal agent classified as a systemic antifungal. This classification indicates its ability to be absorbed into the bloodstream to target pathogens throughout the body. The fundamental therapeutic purpose of Spornar is to control and eliminate fungal infections using its broad-spectrum capability against various fungal species.

Composition, Origin, and Available Forms

The core composition of Spornar is defined by its single active ingredient, itraconazole, which is a compound entirely synthetic in origin and available as a prescription-only medication. The drug is intended for oral administration, delivering the therapeutic compound into the systemic circulation.

Itraconazole is available in two distinct dosage forms for oral use: the capsule and the oral solution (liquid). The distinction between these formulations is a significant factor in its application, as the liquid oral solution is formulated to enhance the drug's solubility, which typically results in higher systemic exposure compared to the capsule formulation. This variation in pharmaceutical preparation influences the absorption characteristics, allowing for the selection of the form best suited to ensure systemic delivery.

What side effects are possible with Spornar?

Possible Side Effects and Safety Information

The safety profile for Spornar (itraconazole) details adverse reactions across several physiological systems, as documented in official regulatory labeling. These reactions are categorized by frequency, ranging from common to rare, and inform specific constraints on the medicine's use.

Adverse reactions are grouped into System-Organ Classes, including the Gastrointestinal, Hepatobiliary, Nervous System, and Cardiac systems. Commonly reported adverse reactions (ge 1% incidence) often include nausea, rash, vomiting, edema, headache, and hypertension.


Serious Adverse Reactions and Constraints

Official documents highlight several serious adverse reactions, which include a Boxed Warning concerning Congestive Heart Failure (CHF) and the potential for serious hepatotoxicity (including acute liver failure and death). Because of these risks, the drug is contraindicated for treating nail fungus in patients with a history or evidence of ventricular dysfunction.

Safety notes also address specific population and duration factors. Caution is noted for older adults and individuals with hepatic or renal impairment due to altered drug exposure. Furthermore, peripheral neuropathy has been reported in patients on long-term therapy, and rare cases of serious liver issues have been observed within the initial month of treatment. The drug has a documented negative inotropic effect (decreased heart contractility) and carries a risk of life-threatening cardiac dysrhythmias when co-administered with certain other medications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile for Spornar (Itraconazole) based on documented clinical manifestations and mandated emergency actions. In the event of a suspected or confirmed overdose, immediate medical attention must be sought due to the potential for severe systemic toxicity. Clinical presentation is often characterized as an exaggeration of known adverse effects.


Documented Manifestations and Severe Outcomes

Overdose presentations most commonly involve gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. Of critical concern, regulatory information notes the potential for serious cardiovascular effects, including the risk of Congestive Heart Failure (CHF), which classifies the scenario as potentially severe or life-threatening.


Management and Emergency Procedures

Official regulatory guidance states that no specific antidote is known for Spornar overdose. Consequently, management is symptomatic and supportive. Procedural steps that may be considered in a healthcare setting include gastric lavage (if performed shortly after ingestion) and the administration of activated charcoal to limit absorption. It is officially noted that the drug is not significantly removed by hemodialysis, a critical consideration for management, particularly in patients with existing renal impairment. Hospital monitoring and observation of vital signs are typically required until stabilization.

Therapeutic Uses of Spornar

What Spornar Treats: Main Uses and Benefits

Spornar (Itraconazole) is a systemic antifungal agent used in the management of specific, often severe, fungal and yeast infections throughout the body, playing a role in managing the underlying pathogens and contributing to easing distressing symptoms.

The medication is indicated for conditions that include systemic mycoses such as Histoplasmosis, Blastomycosis, and certain types of Aspergillosis, as well as localized issues like severe candidiasis of the mouth and esophagus, and persistent onychomycosis (nail fungus).

The therapeutic benefit is commonly used when managing infections that have become systemic or are difficult to clear locally. For patients with systemic disease, Spornar may assist with managing the progression of the illness and is relevant for easing associated symptoms like fever and deep-seated fatigue, supporting the patient’s overall health during a severe episode. For chronic nail and mucosal infections, the medicine helps address visible damage and discomfort.

“This systemic approach provides supportive relief for fungal issues that require managing pathogens throughout the body.”

Quick Fact: Supports relief for symptoms of fungal nail deterioration

In high-risk patient populations, such as those with immunocompromised systems, Spornar may be used as prophylaxis (prevention). This assists with maintaining functional stability during periods where symptoms are more noticeable, supporting the management of systemic fungal diseases.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documents define specific criteria for the use of Spornar (itraconazole) in various patient groups, focusing primarily on cardiac, liver, and reproductive status.

Eligibility Status Official Regulatory Wording
Absolute Contraindication Contraindicated in patients with evidence or a history of Congestive Heart Failure (CHF) for the treatment of onychomycosis (nail fungus).
Absolute Contraindication Contraindicated in pregnant women, except for life-threatening systemic fungal infections. Women of childbearing potential must use effective contraception during and after therapy.
Absolute Contraindication Prohibited for patients with known hypersensitivity to itraconazole or those taking certain drugs that may cause severe cardiac events.
Restricted Use/Caution Strongly discouraged for patients with active liver disease. Use is advised only if the expected benefit in a serious or life-threatening situation exceeds the risk.
Restricted Use/Caution Use is permitted in patients with CHF for systemic infections only if the benefit clearly outweighs the risk.
Restricted Use/Caution Caution is advised in patients with renal impairment (kidney disease) due to limited clinical data.
Not Recommended Pediatric patients (under 18) and older adults are not recommended unless the potential benefit outweighs the potential risks, as efficacy and safety have not been definitively established in these age groups.

These constraints establish strict population boundaries for the medicine, mandating prohibition for absolute contraindications and requiring careful risk-benefit analysis for restricted-use populations, based solely on governmental prescribing information.

What should I know about interactions with other medicines?

Spornar Interactions with other medicines and products

Spornar (itraconazole) is officially documented as a potent inhibitor of both the CYP3A4 enzyme system and the P-glycoprotein (P-gp) transporter. This is a significant pharmacokinetic interaction, which causes the plasma concentration and overall exposure of numerous co-administered medicines to increase due to reduced clearance.

Formal Contraindicated Combinations

The co-administration of Spornar with several medicinal products is strictly forbidden by regulatory authorities. This restriction is based on the risk of elevated plasma concentrations leading to severe outcomes, such as QT prolongation and potentially fatal arrhythmias. Prohibited drug classes include certain Antiarrhythmics (e.g., Dofetilide, Quinidine), HMG CoA-Reductase Inhibitors (e.g., Lovastatin, Simvastatin), Ergot Alkaloids, and certain Sedatives (e.g., Oral Midazolam, Triazolam).

Interactions with Food and Acid Suppressors

The absorption of the Spornar capsule is highly dependent on an acidic gastric environment. Co-administration of the capsule with gastric acid suppressors (e.g., PPIs or H2-receptor antagonists) is documented to reduce itraconazole exposure. Conversely, the capsule's absorption is maximal when taken after a full meal. The oral solution formulation is maximal when taken without food.

Population-Specific Constraints

Official labeling notes that overall itraconazole exposure (AUC) is decreased in patients with moderate and severe renal impairment. Furthermore, due to the drug's hepatic metabolism, patients with impaired hepatic function may exhibit a prolonged elimination half-life, which defines specific constraints when co-administering certain other medicines.

Mechanism of Action

How Spornar works

Spornar (Itraconazole) operates through a primary fungicidal mechanism alongside secondary effects on human physiological systems. The primary mechanism involves the drug acting as an inhibitor of lanosterol 14-alpha-demethylase (CYP51), a crucial enzyme in the ergosterol biosynthesis pathway of the fungal cell. This inhibition prevents the conversion of lanosterol into ergosterol, leading to the severe depletion of ergosterol and the concurrent accumulation of toxic 14-methylated sterols. This mechanistic cascade compromises the structural integrity and permeability of the fungal cell membrane, resulting in the cessation of fungal cell proliferation.

Secondary actions include the inhibition of the human hepatic enzyme CYP3A4, which results in the altered metabolic activity of the CYP3A4 enzyme on other substrates. Furthermore, Spornar engages in signaling interference through the antagonism of the Hedgehog (Smo) pathway and inhibition of VDAC1, leading to the modulation of processes dependent on these mammalian signaling pathways.

Dosage and Administration Information

Spornar (itraconazole) is a systemic antifungal that may be administered via the oral route in capsule, solution, or tablet form, or potentially through an intravenous (IV) route in specialized or inpatient settings. Usage patterns are specific, particularly concerning the timing of administration. The capsule form is typically taken immediately after a full meal to ensure maximal systemic absorption and is generally swallowed whole. Conversely, the oral solution is taken on an empty stomach, for example, one hour before a meal, and the solution is swished briefly in the mouth before being swallowed when treating mucosal infections. Due to these distinct absorption requirements, the different formulations are not interchangeable at the same dose.

Treatment follows varied dosing schedules and durations based on the specific condition. For severe systemic mycoses, a high initial loading dose of, for example, 200 mg three times daily may be administered for the first three days, followed by a lower maintenance dose. Dosing can range from 100 mg to 400 mg daily, with doses over 200 mg typically given in divided doses. The duration of therapy is variable, ranging from a few weeks for acute infections to three to twelve months for deep-seated systemic disease. For localized conditions like fingernail onychomycosis, a specific cyclic regimen (pulse therapy) is used, alternating administration periods with non-treatment weeks. Furthermore, patients with hepatic or renal impairment may require specialized monitoring and dose adjustments due to altered drug metabolism.

Recent Clinical Evidence

Research evidence / Overview of studies for Spornar (Itraconazole)


Evidence for Systemic Fungal Infections (Mycoses)

Research focusing on Spornar for serious deep-seated fungal infections, such as Blastomycosis and Histoplasmosis, has been conducted using both non-comparative open-label studies and comparative controlled trials. Researchers examined how patients responded over time, with primary measured outcomes related to systemic or functional imbalance. Studies reported that certain proportions of the patients evaluated met the defined clinical and mycological endpoints. For Aspergillosis, research has explored its evaluation in patients whose condition was refractory to or could not tolerate other established treatments.

Evidence for Localized and Mucosal Infections

Research focusing on Spornar for more common, localized conditions like Onychomycosis (nail fungus) and Candidiasis (yeast infections of the mouth and esophagus), includes Randomized Controlled Trials (RCTs). Trials against placebo describe patterns of mycological cure and visible nail improvement in the observed patient groups. However, the high rate of relapse after treatment for onychomycosis is a known factor, and long-term outcomes are not fully established.

Research on Prophylaxis (Preventive Use)

Research focusing on Spornar for the preventive use in high-risk patients was evaluated in numerous RCTs and meta-analyses. Studies reported that certain proportions of the patients evaluated met the defined clinical and mycological endpoints; meta-analyses have reported that the treatment may be associated with a lower incidence of Invasive Fungal Infections (IFIs) compared to placebo or certain older antifungals.

Evidence Gaps and Uncertainty

Evidence in Specific Patient Groups is often based on small observational cohorts. Subgroup findings are uncertain for specific populations, such as children and some groups of older adults. The challenge of variable absorption across patients and formulations remains a key area of uncertainty, which is why therapeutic drug monitoring was explored in some research settings to address this variability. Data for certain severe infection sites, particularly fungal infections in the central nervous system (CNS), remain insufficient.

Key Studies & References

  1. Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America (IDSA)
  2. Clinical Practice Guideline for the Diagnosis and Management of Aspergillosis: 2016 Update by IDSA (Includes Prophylaxis and TDM)

Frequently Asked Questions (FAQ)

Common questions about Spornar (FAQ)


Q: How quickly should I expect to feel the effects of Spornar?

Peak concentrations of the medicine in the bloodstream are typically reached within 2 to 5 hours after a dose. However, official information indicates that the overall duration of treatment for fungal infections is often long, and it may take weeks or even months before a patient notices a significant improvement in symptoms.


Q: How soon after starting Spornar should my symptoms improve?

The time it takes for symptoms to improve depends heavily on the type and location of the infection being treated. For conditions like toenail fungus, regulatory information states that the final cure may not be fully achieved until several months after the course is finished, as a healthy nail takes time to grow out.


Q: What is the difference between Spornar and other similar medications?

Spornar (itraconazole) is defined as a a synthetic triazole antifungal agent. Official regulatory documents state that its primary mechanism of action involves blocking a crucial enzyme needed by fungal cells to build their cell membranes. This classification defines how it works compared to other types of antifungals.


Q: Can children take Spornar?

The official product labeling indicates that the safety and effectiveness of Spornar have not been definitively established in pediatric patients (under 18). Its use in children is generally not recommended unless a healthcare provider must carefully weigh the potential benefits against the potential risks.


Q: Is Spornar safe for use in older adults?

Regulatory documents advise caution when Spornar is used in older adults. This is because this population may have a greater frequency of decreased function in organs like the liver, kidneys, or heart, which can affect how the medicine works in the body. These factors require careful consideration by a healthcare professional.


Q: Does Spornar need to be taken with food?

Yes, but this is different depending on the specific form of the medicine. Regulatory instructions state that Spornar capsules must be taken immediately after a full meal to ensure proper absorption. Conversely, the oral solution should be taken without food to maximize its effectiveness.


Q: Why is Spornar sometimes prescribed in combination with other drugs?

Spornar is officially indicated for the treatment of severe systemic fungal infections. In clinical practice, these serious infections may sometimes follow or require combination therapy to ensure complete coverage or for special patient needs. Official documents contain extensive details on how Spornar interacts with numerous other medicines.


Q: Can I drink alcohol while taking Spornar?

Regulatory documents indicate a risk of serious hepatotoxicity (liver problems), including liver failure, with Spornar use. Therefore, caution is advised regarding its use with other substances, including alcohol, that may put stress on the liver. Combining it with alcohol requires review by a healthcare professional.


Q: Is it common to have stomach upset from Spornar?

Yes, common adverse reactions reported in clinical trials include gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain. Patients experiencing bothersome side effects should consult their prescribing physician.


Q: What does the package insert say about the efficacy of Spornar?

Official package inserts and clinical studies describe that trials demonstrated defined clinical and mycological success rates in patients with various fungal infections. This includes deep-seated infections like blastomycosis and more common ones like onychomycosis.


Q: What happens if I miss a dose of Spornar?

Official patient information addresses what to do in the event of a missed dose. These instructions are typically detailed in the patient information leaflet and should be reviewed with a healthcare professional to ensure the correct course of action is taken.


Q: Can Spornar cause weight gain or weight loss?

Official warnings identify sudden weight gain as a potential sign of Congestive Heart Failure, a serious risk associated with this medicine. Regulatory warnings indicate that if this symptom occurs, a healthcare professional should be contacted immediately.


Q: Is it normal to feel tired when starting Spornar?

Yes, both fatigue and excessive tiredness are listed among the reported adverse reactions in official documents. Furthermore, excessive tiredness is also listed as a potential warning sign of Congestive Heart Failure, and this symptom should be discussed with a healthcare professional.


Q: Can I take Spornar with over-the-counter pain medication like ibuprofen?

Spornar is known to be a strong inhibitor of a liver enzyme called CYP3A4, which can increase the concentration of many other medicines, including some over-the-counter drugs. While not all pain relievers are strictly forbidden, all combinations should be reviewed by a healthcare provider.


Q: How long does Spornar stay in your system after stopping it?

The official product information states that the medicine's half-life increases with repeated dosing. Once treatment is stopped, Spornar plasma concentrations typically decrease to an almost undetectable level within 7 to 14 days.


Q: Do I need to avoid any specific foods or drinks while on Spornar?

The absorption of the capsule form is dependent on stomach acid, and specific foods or drinks may enhance or diminish absorption. It is important to check with a healthcare provider about any specific dietary restrictions, as certain fruit juices, like grapefruit juice, are known to be strong enzyme inhibitors that could interact with the drug.


Q: Can Spornar affect my ability to drive or operate machinery?

Yes, the official labeling warns that adverse reactions such as dizziness, blurred vision, or double vision have been reported. Patients are advised not to drive or operate complex machinery until they know how this medicine affects them, as adverse reactions may impair function.


Q: What happens if Spornar stops working for me?

In certain patient populations, such as those with severely compromised immune systems, the amount of medicine absorbed into the body may be decreased. Official documents advise that if a patient is not responding to treatment, the dose may need adjustment, or alternative therapy may need to be considered by the prescribing physician.


Q: Is Spornar addictive?

Regulatory documents list drug abuse and dependence information for all approved products. Spornar is not classified as a controlled substance by US or international regulatory agencies and has no known addiction potential.


Q: What should I do if a side effect of Spornar feels bothersome?

Official patient information advises that bothersome side effects should be discussed with a healthcare professional for guidance. This is crucial for managing discomfort and ensuring the prescribed treatment remains appropriate.


Q: Does Spornar cause sun sensitivity?

Yes, official safety information collected during post-marketing experience has specifically reported cases of photosensitivity (increased sensitivity to the sun) in patients taking Spornar. Patients should discuss necessary precautions for sun exposure with their healthcare provider.


Q: Is Spornar considered a high-risk medication?

Spornar is a potent prescription drug and carries a Boxed Warning in the US labeling regarding the risks of Congestive Heart Failure and potential serious hepatotoxicity (liver damage). These risks mean its use requires careful assessment by a doctor, and it is contraindicated (forbidden) for treating nail fungus in patients with a history of heart problems.


Q: What is the typical duration of treatment with Spornar?

The duration of treatment is highly variable and depends entirely on the specific infection being treated. Official dosing recommendations provide examples ranging from short courses of 1 to 2 weeks for certain yeast infections, up to 6 to 12 months for serious systemic infections.


Q: Can Spornar be cut in half or crushed?

The official instructions for Spornar capsules state that they should generally be swallowed whole. Because the capsule's design is critical for the medicine's absorption, altering its form by cutting, crushing, or chewing may change how much medicine gets into the bloodstream and could impact its effectiveness.


Q: Are there specific symptoms that mean I should call a doctor immediately about Spornar?

Yes, regulatory documents highlight the need to stop the medication and seek immediate medical attention if a patient experiences signs of serious adverse reactions. This includes symptoms of heart failure (e.g., shortness of breath, sudden weight gain) or liver problems (e.g., yellowing of the skin or eyes, dark urine).


Q: Can taking Spornar cause changes in mood or anxiety?

Official safety documents include reports of adverse reactions in the Nervous System and psychological disorders. Though not common, symptoms such as nervousness and depression have been reported. Any changes in mood or anxiety should be reported to a healthcare provider.


Q: What are the ingredients in Spornar besides the active drug?

The official package insert lists the inactive ingredients in the medicine, which are substances used to form the product, such as binders, fillers, and colorants. For the capsule, this includes materials like sugar spheres and gelatin. The oral solution contains various other excipients, such as sorbitol.


Q: Is Spornar available without a prescription in some countries?

In major regulatory jurisdictions, including the United States, Canada, the United Kingdom, and Australia, Spornar is classified as a prescription-only medicine (POM or Rx-only). It requires a valid prescription from an authorized healthcare professional.


Q: Can I split the daily dose of Spornar?

Official dosing guidelines state that for daily doses exceeding 200 mg, the medicine is typically given in divided doses (e.g., twice daily). Patients should follow the specific dosing instructions provided by their healthcare professional.


Q: Why is consistency important when taking Spornar?

Consistency is critical because the medicine takes time to reach its full therapeutic effect, accumulating in the body during repeated dosing. Official studies show it can take around 15 days of consistent dosing to reach the necessary steady-state concentrations in the bloodstream. Maintaining consistency is necessary to keep levels high enough to prevent the infection from returning.


Q: Are there any dietary restrictions that enhance or diminish Spornar's effect?

The absorption of the capsule form is known to be reduced by medicines that lower stomach acid. While general dietary restrictions are not specified, all combinations of food, supplements, and other medicines must be reviewed by a healthcare provider, as some may interact and alter the drug's effect.


Q: Are there generic versions of Spornar available?

Yes, official regulatory resources, such as the FDA's Orange Book, confirm that generic versions of the 100 mg oral capsule formulation have been approved for use. However, generic versions of the oral solution and injectable products may not be available.


Q: Does Spornar require special monitoring or blood tests?

Yes, due to the potential for serious hepatotoxicity (liver damage), official warnings recommend that liver function monitoring be considered for all patients taking Spornar. Additional monitoring may be considered for certain severe infections or for patients with specific health conditions.


Q: Can Spornar affect blood pressure?

Yes, hypertension (high blood pressure) is listed in the official documents as one of the commonly reported adverse reactions experienced during clinical trials with Spornar. Any concerns regarding blood pressure should be discussed with a doctor.

How should Spornar be stored and disposed of?

Official Storage and Disposal Instructions for Sporanox (Itraconazole)

Sporanox must be stored and disposed of according to strict conditions defined in government regulatory labeling to ensure product integrity and safety.


Storage Requirements

Formulation Required Storage Condition
Capsules Store at controlled room temperature, between 59 F and 77 F (15 C and 25 C). The capsules must be protected from both light and moisture.
Oral Solution Store at or below 77 F (25 C). Do not freeze the oral solution.

The medicine must be kept in its original, tightly closed container and stored out of the sight and reach of children.

Disposal

Expired or unused Sporanox must be thrown away. Disposal must be conducted according to local pharmaceutical waste regulations. Consult a healthcare professional or pharmacist for guidance on proper discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spornar found in:

A-Z Index: